These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 18998758)

  • 1. Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).
    Ross Terres JA; Lozano-Ortega G; Kendall R; Sculpher MJ
    BMC Cardiovasc Disord; 2015 Dec; 15():180. PubMed ID: 26715178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Images in Vascular Medicine: A case of recurrent hemorrhagic bullae from enoxaparin and then fondaparinux.
    Ghorbanzadeh A; Houghton D
    Vasc Med; 2023 Dec; 28(6):616-617. PubMed ID: 37698281
    [No Abstract]   [Full Text] [Related]  

  • 3. A rare case of fondaparinux-induced major bleeding in postmenopausal woman prescribed for non-ST segment elevation Ml.
    Tandon VR; Sharma S; Mahajan S; Mahajan A; Khajuria V
    J Midlife Health; 2013 Oct; 4(4):241-3. PubMed ID: 24381468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
    ; Mehta SR; Yusuf S; Granger CB; Wallentin L; Peters RJ; Bassand JP; Budaj A; Joyner C; Chrolavicius S; Fox KA
    Am Heart J; 2005 Dec; 150(6):1107. PubMed ID: 16338245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
    Fox KA; Bassand JP; Mehta SR; Wallentin L; Theroux P; Piegas LS; Valentin V; Moccetti T; Chrolavicius S; Afzal R; Yusuf S;
    Ann Intern Med; 2007 Sep; 147(5):304-10. PubMed ID: 17785485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on fondaparinux sodium in acute coronary syndromes.
    Blick SK; Orman JS; Wagstaff AJ; Scott LJ
    BioDrugs; 2008; 22(6):413-5. PubMed ID: 18998758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
    Blick SK; Orman JS; Wagstaff AJ; Scott LJ
    Am J Cardiovasc Drugs; 2008; 8(2):113-25. PubMed ID: 18422394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fondaparinux: a pharmacoeconomic review of its use in the management of non-ST-segment elevation acute coronary syndrome.
    McKeage K; Lyseng-Williamson KA
    Pharmacoeconomics; 2010; 28(8):687-98. PubMed ID: 20617858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor Xa inactivation in acute coronary syndrome.
    Barantke M; Bonnemeier H
    Curr Pharm Des; 2008; 14(12):1186-90. PubMed ID: 18473865
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.